Free Trial

Nektar Therapeutics (NKTR) 10K Form and Latest SEC Filings 2026

Nektar Therapeutics logo
$83.37 -1.72 (-2.02%)
Closing price 04:00 PM Eastern
Extended Trading
$83.57 +0.20 (+0.24%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Nektar Therapeutics SEC Filings & Recent Activity

Nektar Therapeutics (NASDAQ:NKTR) has submitted 513+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Nektar Therapeutics's financial statements. The most recent filing was a Form 8-K submitted on May 7, 2026.

Form 4
NEKTAR THERAPEUTICS Reports Ownership Change on Feb. 20, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Nektar Therapeutics Files Current Report on May. 7, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

Nektar Therapeutics SEC Filing History

Browse Nektar Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/07/2026 3:30 PM
Nektar Therapeutics (906709) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/06/2026 10:30 AM
FMR LLC (315066) Filed by
Nektar Therapeutics (906709) Subject
Form SCHEDULE 13G/A
04/24/2026 3:15 PM
Nektar Therapeutics (906709) Filer
Form DEF 14A
04/24/2026 3:16 PM
Nektar Therapeutics (906709) Filer
Form DEFA14A
04/24/2026 3:18 PM
Nektar Therapeutics (906709) Filer
Form ARS
04/23/2026 5:02 AM
Nektar Therapeutics (906709) Filer
Form 424B5
04/23/2026 5:06 AM
Nektar Therapeutics (906709) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/20/2026 3:58 PM
Nektar Therapeutics (906709) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/20/2026 4:00 PM
Nektar Therapeutics (906709) Filer
Form 424B5
04/20/2026 7:02 AM
Nektar Therapeutics (906709) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/17/2026 8:00 AM
Nektar Therapeutics (906709) Subject
Two Seas Capital LP (1823138) Filed by
Form SCHEDULE 13G
03/27/2026 9:48 AM
Nektar Therapeutics (906709) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/13/2026 12:04 PM
Nektar Therapeutics (906709) Subject
Wilson Mark Andrew (1808356) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/12/2026 3:45 PM
Nektar Therapeutics (906709) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/06/2026 9:05 AM
FMR LLC (315066) Filed by
Nektar Therapeutics (906709) Subject
Form SCHEDULE 13G
02/20/2026 6:10 PM
Nektar Therapeutics (906709) Issuer
ROBIN HOWARD W (1206869) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 6:10 PM
Nektar Therapeutics (906709) Issuer
Zalevsky Jonathan (1789857) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/18/2026 2:15 PM
Nektar Therapeutics (906709) Subject
Zalevsky Jonathan (1789857) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/10/2026 7:05 AM
Nektar Therapeutics (906709) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/22/2026 6:31 PM
Nektar Therapeutics (906709) Issuer
Zalevsky Jonathan (1789857) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 5:01 PM
Nektar Therapeutics (906709) Issuer
ROBIN HOWARD W (1206869) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 5:01 PM
Nektar Therapeutics (906709) Issuer
Zalevsky Jonathan (1789857) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 7:00 AM
Nektar Therapeutics (906709) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/25/2025 7:28 PM
Nektar Therapeutics (906709) Issuer
ROBIN HOWARD W (1206869) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/25/2025 7:29 PM
Nektar Therapeutics (906709) Issuer
Wilson Mark Andrew (1808356) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/25/2025 7:30 PM
Nektar Therapeutics (906709) Issuer
Zalevsky Jonathan (1789857) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/25/2025 2:35 PM
Nektar Therapeutics (906709) Subject
ROBIN HOWARD W (1206869) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/25/2025 2:28 PM
Nektar Therapeutics (906709) Subject
Zalevsky Jonathan (1789857) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/25/2025 2:32 PM
Nektar Therapeutics (906709) Subject
Wilson Mark Andrew (1808356) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/21/2025 3:06 PM
Nektar Therapeutics (906709) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2025 4:45 PM
Nektar Therapeutics (906709) Subject
SUSQUEHANNA SECURITIES, LLC (1446580) Filed by
Form SCHEDULE 13G
11/12/2025 3:06 PM
Nektar Therapeutics (906709) Filer
Form S-3ASR
11/12/2025 3:09 PM
Nektar Therapeutics (906709) Filer
Form 424B5
11/10/2025 5:31 AM
Nektar Therapeutics (906709) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/31/2025 10:05 AM
Nektar Therapeutics (906709) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
10/01/2025 6:49 PM
Ajer Jeffrey Robert (1557533) Reporting
Nektar Therapeutics (906709) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/01/2025 6:50 PM
Brainard Diana (1818070) Reporting
Nektar Therapeutics (906709) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/01/2025 6:51 PM
CHESS ROBERT (1227886) Reporting
Nektar Therapeutics (906709) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/01/2025 6:51 PM
GREER R SCOTT (1211703) Reporting
Nektar Therapeutics (906709) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/01/2025 6:52 PM
Nektar Therapeutics (906709) Issuer
WHITFIELD ROY A (936728) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/18/2025 7:56 AM
Nektar Therapeutics (906709) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/11/2025 8:01 PM
Nektar Therapeutics (906709) Issuer
ROBIN HOWARD W (1206869) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/09/2025 3:57 PM
Nektar Therapeutics (906709) Subject
ROBIN HOWARD W (1206869) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/08/2025 7:31 PM
Nektar Therapeutics (906709) Issuer
ROBIN HOWARD W (1206869) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/08/2025 7:32 PM
Nektar Therapeutics (906709) Issuer
Zalevsky Jonathan (1789857) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2025 3:37 PM
Nektar Therapeutics (906709) Subject
ROBIN HOWARD W (1206869) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/04/2025 8:01 PM
Nektar Therapeutics (906709) Issuer
ROBIN HOWARD W (1206869) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/04/2025 8:02 PM
Nektar Therapeutics (906709) Issuer
Zalevsky Jonathan (1789857) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/04/2025 4:06 PM
Nektar Therapeutics (906709) Subject
ROBIN HOWARD W (1206869) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/02/2025 3:42 PM
Nektar Therapeutics (906709) Subject
ROBIN HOWARD W (1206869) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/02/2025 3:45 PM
Nektar Therapeutics (906709) Subject
Zalevsky Jonathan (1789857) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/21/2025 8:03 PM
Nektar Therapeutics (906709) Issuer
ROBIN HOWARD W (1206869) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/21/2025 8:04 PM
Nektar Therapeutics (906709) Issuer
Wilson Mark Andrew (1808356) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/21/2025 8:05 PM
Nektar Therapeutics (906709) Issuer
Zalevsky Jonathan (1789857) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/19/2025 2:20 PM
Nektar Therapeutics (906709) Subject
Zalevsky Jonathan (1789857) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/18/2025 11:10 AM
BlackRock, Inc. (2012383) Filed by
Nektar Therapeutics (906709) Subject
Form SCHEDULE 13G/A
07/09/2025 3:39 PM
BIOTECHNOLOGY VALUE FUND L P (918923) Filed by
Nektar Therapeutics (906709) Subject
Form SCHEDULE 13G
07/03/2025 1:07 PM
INTEGRATED CORE STRATEGIES (0) US
Nektar Therapeutics (906709) Subject
Form SCHEDULE 13G
07/01/2025 3:44 PM
Nektar Therapeutics (906709) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/27/2025 4:15 PM
Nektar Therapeutics (906709) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/24/2025 6:45 AM
Nektar Therapeutics (906709) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/06/2025 3:30 PM
Nektar Therapeutics (906709) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/04/2025 3:30 PM
Nektar Therapeutics (906709) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/21/2025 7:07 PM
Nektar Therapeutics (906709) Issuer
ROBIN HOWARD W (1206869) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2025 7:07 PM
Nektar Therapeutics (906709) Issuer
Wilson Mark Andrew (1808356) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2025 7:08 PM
Nektar Therapeutics (906709) Issuer
Zalevsky Jonathan (1789857) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)

Nektar Therapeutics SEC Filings - Frequently Asked Questions

Nektar Therapeutics (NKTR) has submitted 513+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Nektar Therapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Nektar Therapeutics's financial statements page.

The most recent filing was a Form 8-K submitted on May 7, 2026. This was a current report on a material business event.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:NKTR) was last updated on 5/7/2026 by MarketBeat.com Staff.
From Our Partners